Santiago de Compostela, Spain
Santiago de Compostela, Spain

The University of Santiago de Compostela - USC is a public university located in the city of Santiago de Compostela, Galicia, Spain. A second campus is located in Lugo, Galicia. It is one of the world's oldest universities in continuous operation.The university traces its roots back to 1495, when a school was opened in Santiago. In 1504, Pope Julius II approved the foundation of a university in Santiago but "the bull for its creation was not granted by Clement VII until 1526". In 1555 the institute began to separate itself from strictly religious instruction with the help of Cardinal Juan Álvarez de Toledo and started to work towards developing other academic fields, including the emerging science fields.Today the university's facilities cover more than 1,300,000 square meters . In terms of human resources, the university has more than 2,000 teachers involved in study and research, over 42,000 students, and more than 1,000 people working in administration and services. Moreover, in 2009, the University received the accreditation of Campus of International Excellence by the Ministry of Education , recognising USC as one of the most prestigious universities in Spain.The university ranks 5th in Spain's best universities ranking by Complutense University of Madrid and IAIF and 4th amongst public universities. Wikipedia.


Time filter

Source Type

Patent
Sanofi S.A. and University of Santiago de Compostela | Date: 2015-06-12

Nanocapsule systems of at least one active pharmaceutical ingredient selected from the group consisting of at least one insulin, insulin analogue, insulin derivative, glucagon-like peptide-1 receptor agonist (GLP1 R agonist) and/or dual GLP-1 receptor/glucagon receptor agonist and/or or any combination thereof are disclosed.


Patent
Fundacion Pedro Barrie De La Maza, Sergas, University of Santiago de Compostela, Fundacion Ramon Dominguez and Biomerix | Date: 2015-04-30

The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.


Patent
University of Vigo and University of Santiago de Compostela | Date: 2017-01-11

The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing pharmaceutical compositions intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinsons disease (PD), Alzheimers disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.


Patent
University of Santiago de Compostela | Date: 2017-01-04

The invention relates to a method and a system for struvite crystallization of in order to recover phosphates in urban or industrial wastewater preferably having phosphate concentrations higher than 50 mg P/L, more preferably higher than 100 mg P/L, where phosphates are recovered by means of the crystallization thereof in the form of struvite granules, the diameter of which can reach up to 5 mm. The struvite crystallization system is formed by a crystallizer (1), a decanter (2) with a distribution system (9), and a unit for adding industrial magnesium hydroxide (3). The phosphates are recovered from the wastewater as a result of two steps : a step of growing struvite granules, and a step of growing fine struvite crystals.


Patent
Sanofi S.A. and University of Santiago de Compostela | Date: 2017-04-19

Nanocapsule systems of at least one active pharmaceutical ingredient selected from the group consisting of at least one insulin, insulin analogue, insulin derivative, glucagon-like peptide-1 receptor agonist (GLP1 R agonist) and/or dual GLP-1 receptor/glucagon receptor agonist and/or or any combination thereof are disclosed.


The invention relates to a temperature-measuring device, to a method for manufacturing the device, and system for measuring point of impact incorporated in the device. According to one aspect, the invention relates to a temperature-measuring device including a sheet of thin film made of magnetic-metallic material such that, in use and the presence of an applied magnetic field, a change of temperature in one area of the sheet generates an electric voltage in the area, the generated electric voltage being readable by an electric voltage reader corresponding to the area. According to another aspect, the invention relates to a method for manufacturing the device. According to yet another aspect, the invention refers to a system, incorporated in the device, to measure point of impact, radiation, or particles.


Patent
Sergas, University of Santiago de Compostela and Biomerix | Date: 2017-03-08

The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.


Patent
University of Santiago de Compostela | Date: 2017-04-12

The present invention refers to A pharmaceutical composition comprising (i) poloxamer 407, (ii) at least one penetration enhancer, (iii) at least one solubilizing agent selected from the group consisting of cyclodextrins, hydrophilic polymers and mixtures thereof, (iv) at least one biologically active substance, and (v) a vehicle comprising water and a C1-C3 alcohol, or mixtures thereof.


Patent
University of Santiago de Compostela and Institute Salud Carlos Iii | Date: 2017-04-19

The present invention provides a nanoparticulate system or composition which comprises nanoparticles comprising a core of a sorbitan ester, a surface layer of a cationic substance and a gene construct consisting of plasmid DNA, wherein the gene construct is physically bound to the cationic substance, for use in a method of treatment by gene therapy, in particular for medical applications by using gene therapy in the ophthalmic sector.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-10-2016 | Award Amount: 6.00M | Year: 2017

The overall objective of B-SMART is: 1. to design modular nanoparticles, 2. to manufacture them via a quality-by-design protocol, 3. to achieve delivery of therapeutic RNAs to the brain and treat neurodegenerative diseases. I. To design modular nanoparticles consisting of o an active RNA payload o established (lipid-based), emerging (trigger-responsive polymer-based) or exploratory (extracellular vesicle-based) nanoparticles o a targeting ligand consisting of the variable domain of heavy chain only antibodies (also known as VHHs or nanobodies), which are coupled to the carrier platform II. To manufacture the modular nanoparticles using a microfluidic assembly system that will ensure quality-by-design: uniform nanoparticles across research sites and excellent control over the physico-chemical parameters. III. To test pre-clinical activity of formulations with promising in vitro activity with good cell/blood compatibility and to select the best RNA-formulation for clinical translation to treat neurodegenerative diseases. Pre-clinical efficacy is tested after o local injection o nasal administration o systemic administration The neurodegenerative diseases carry a high burden for patients since they are without exception progressive. But they also carry a substantial socio-economic burden with estimated costs of 130 billion euro. per year (2008). IV. The technical work in B-SMART will be supported by project management. It ensures that the project is coordinated in a clear, unambiguous and mutually acceptable manner and that the project achieves its objectives, within the given financial and time constraints. in B-SMART we expect to arrive at a scale-able nanoparticle formulation with uniform characteristics that shows strong pre-clinical evidence of therapeutic efficacy and is ready for clinical translation.

Loading University of Santiago de Compostela collaborators
Loading University of Santiago de Compostela collaborators